Heart and Blood Diseases

All Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Vascular Diseases

Lung Diseases

Thrombosis

Pulmonary Embolism

Embolism

Embolism and Thrombosis

Respiratory Tract Diseases

Coagulants

All Drugs and Chemicals

Fibrin fragment D

Patients randomized to this arm will be evaluated according to the YEARS algorithm.

Patients randomized to this arm will undergo a contrast enhanced CTPA.

Patients randomized to the YEARS algorithm will be evaluated according to the YEARS algorithm consisting of three items of the original Wells rule (clinical signs of DVT, haemoptysis and 'PE most likely diagnosis') and a D-dimer test. In patients without any of the three items and a D-dimer level \<1.0 μg/mL (\<1000ng/mL), and in patients with ≥1 items and a D-dimer level \<0.5 μg/mL (\<500 ng/mL) a PE is excluded without CTPA. In the other patients a standard contrast enhanced CTPA will be performed according to local practice. PE is defined as at least one filling defect in the pulmonary artery tree on CTPA.

YEARS algorithm

Patients randomized to the CTPA management group will undergo a contrast enhanced CTPA to rule out PE according to standard local practice.

CTPA

Emily MARTENS, MD

Menno HUISMAN, Pr

Jo RASKIN, Dr

Andrea PENALOZA, Pr

Alexandre GHUYSEN, Pr

Francis COUTURAUD, Pr

Jeannot SCHMIDT, Pr

Isabelle MAHE, Pr

Olivier SANCHEZ, Pr

Laurent BERTOLETTI, Dr

Giorgio COSTANTINO, Pr

Roberto POLA, Dr

Marije ten WOLDE, Dr

Michiel COPPENS, Dr

Marcel HOVENS, Dr

Marco GROOTENBOERS, Dr

Rolf BROUWER, Dr

Yordi VAN DOOREN

Pieter Willem KAMPHUISEN, Pr

Jenneke LEENTJENS, Dr

Reinier Albert SPRENGER

Mariëlle DE VREEDE

Martje MAAS

René VAN DER GRIEND, Dr

David Jiménez, Pr

Tobias TRITSCHLER, Dr

Marc RIGHINI, Pr

Olivier HUGLI, Dr

The aim of this study is to prospectively validate the safety and efficiency of management according to the YEARS algorithm to safely rule out clinically suspected PE in patients with active malignancy to be compared with 'standard' management by computed tomography pulmonary angiography (CTPA) alone in a randomized study.

Recently, the YEARS-algorithm was demonstrated to be a safe and efficient diagnostic strategy for patients with clinically suspected pulmonary embolism (PE). It is recognized that diagnostic algorithms for pulmonary embolism (PE) may not be as effective and safe in patients with malignancy, due to the low specificity of D-dimer test in that setting. A diagnostic algorithm that could safely rule out PE in patients with malignancy without performing computed tomography pulmonary angiography (CTPA) could nonetheless improve patient care.

Safety and Efficiency of the YEARS Algorithm Versus Computed Tomography Pulmonary Angiography Alone for Suspected Pulmonary Embolism in Patients With Malignancy

Safety and Efficiency of the YEARS Algorithm Versus Computed Tomography Pulmonary Angiography Alone for Suspected Pulmonary Embolism in Patients With Malignancy : HYDRA Study

Spots Global Cancer Trial Database for ctpa

Every month we try and update this database with for ctpa cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for ctpa

Every month we try and update this database with for ctpa cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for ctpa cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.